Description
Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company’s initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).
Products include Emricasan, an orally active caspase protease inhibitor for the treatment of acute-on-chronic liver failure and chronic liver failure, as well as for the patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection. The company was founded in 2005 and is headquartered in San Diego, California.
Address
Suite 200, 4365 Executive Drive
SAN DIEGO, CA 92121
United States
SAN DIEGO, CA 92121
United States
Website
www.conatuspharma.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -372.19% | -69.70% |
| Return on average equity | - | - |
| Employees | 13 |
No comments:
Post a Comment